1. Home
  2. BFRI vs BGLC Comparison

BFRI vs BGLC Comparison

Compare BFRI & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biofrontera Inc.

BFRI

Biofrontera Inc.

HOLD

Current Price

$0.81

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$2.46

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFRI
BGLC
Founded
1997
2017
Country
United States
Malaysia
Employees
93
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
10.1M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BFRI
BGLC
Price
$0.81
$2.46
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.75
N/A
AVG Volume (30 Days)
104.5K
6.8K
Earning Date
03-19-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.78
EPS
N/A
N/A
Revenue
N/A
$9,510,646.00
Revenue This Year
$11.67
N/A
Revenue Next Year
$19.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.23
52 Week High
$1.18
$15.19

Technical Indicators

Market Signals
Indicator
BFRI
BGLC
Relative Strength Index (RSI) 42.98 48.41
Support Level $0.80 $2.12
Resistance Level $0.89 $2.73
Average True Range (ATR) 0.05 0.13
MACD -0.01 0.03
Stochastic Oscillator 23.76 60.73

Price Performance

Historical Comparison
BFRI
BGLC

About BFRI Biofrontera Inc.

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: